Concepedia

Maryam Shahidi

MS

Statistics

Publications

24

Citations

1.2K

H-Index

16

Active since

2001

Affiliations

Mazandaran University of Medical Sciences(Current)

Tarbiat Modares University

Royal Marsden NHS Foundation Trust

Boehringer Ingelheim (United Kingdom)

Shahid Beheshti University of Medical Sciences

Maryam Shahidi is an author at Mazandaran University of Medical Sciences specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2001–2023

24

Publications

24

Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer

Robert Huddart, A. Norman, Maryam Shahidi et al. · Journal of Clinical Oncology · 2003 · 548 citations

, , +14

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

Y. Y. Janjigian, Harry J.M. Groen, Leora Horn et al. · Journal of Clinical Oncology · 2011 · 144 citations

, , +17

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)

Haruyasu Murakami, Tomohide Tamura, Toshiaki Takahashi et al. · Cancer Chemotherapy and Pharmacology · 2011 · 85 citations

, , +9

A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

Chen Yang, Jen-Fu Shih, Wenmei Su et al. · Journal of Clinical Oncology · 2010 · 49 citations

, , +17

Radiation sensitivity of leukocytes from healthy individuals and breast cancer patients as measured by the alkaline and neutral comet assay

Maryam Shahidi, Hossein Mozdarani, Peter E. Bryant · Cancer Letters · 2007 · 43 citations

, , +17

1–5 of 24